Immunotherapy in Lymphoma

Recruiting now

Conditions studied: Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma, Burkitt Lymphoma

In brief

The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies? Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes. Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.

Key facts

Study ID
NCT06796517
Run by
Sung-Soo Park
People needed
72
Starts
2024-06-26
Expected to finish
2025-12-31
Last updated by the study team
2025-01-28

Who can join

Age: 19 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.